Pacer Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $461M | Buy |
7,995,711
+67,613
| +0.9% | +$3.88M | 1.17% | 2 |
|
|
2026
Q1 | $481M | Sell |
7,928,098
-451,041
| -5% | -$26.3M | 1.35% | 2 |
|
|
2025
Q4 | $452M | Sell |
8,379,139
-925,559
| -10% | -$44.5M | 1.15% | 7 |
|
|
2025
Q3 | $420M | Sell |
9,304,698
-410,744
| -4% | -$19.2M | 1.06% | 21 |
|
|
2025
Q2 | $450M | Buy |
9,715,442
+772,450
| +9% | +$37.9M | 1.12% | 19 |
|
|
2025
Q1 | $545M | Sell |
8,942,992
-950,565
| -10% | -$55.4M | 1.28% | 8 |
|
|
2024
Q4 | $560M | Sell |
9,893,557
-1,024,069
| -9% | -$57.2M | 1.21% | 4 |
|
|
2024
Q3 | $565M | Sell |
10,917,626
-1,293,576
| -11% | -$60.7M | 1.19% | 1 |
|
|
2024
Q2 | $507M | Buy |
12,211,202
+3,064,247
| +34% | +$137M | 1.15% | 5 |
|
|
2024
Q1 | $496M | Buy |
9,146,955
+1,316,007
| +17% | +$67M | 1.14% | 5 |
|
|
2023
Q4 | $402M | Buy |
7,830,948
+2,540,360
| +48% | +$133M | 1.14% | 10 |
|
|
2023
Q3 | $307M | Buy |
5,290,588
+1,249,846
| +31% | +$76.6M | 1.18% | 20 |
|
|
2023
Q2 | $258M | Sell |
4,040,742
-8,330
| -0.2% | -$559K | 1.04% | 23 |
|
|
2023
Q1 | $281M | Buy |
4,049,072
+3,863,095
| +2,077% | +$272M | 1.2% | 11 |
|
|
2022
Q4 | $13.4M | Sell |
185,977
-1,995,039
| -91% | -$150M | 0.07% | 227 |
|
|
2022
Q3 | $155M | Buy |
2,181,016
+251,581
| +13% | +$18.2M | 1.08% | 8 |
|
|
2022
Q2 | $149M | Buy |
1,929,435
+666,543
| +53% | +$50.8M | 1.1% | 8 |
|
|
2022
Q1 | $92.2M | Buy |
1,262,892
+643,750
| +104% | +$43.2M | 0.76% | 15 |
|
|
2021
Q4 | $38.6M | Buy |
619,142
+162,036
| +35% | +$9.51M | 0.4% | 31 |
|
|
2021
Q3 | $27M | Buy |
457,106
+67,741
| +17% | +$4.46M | 0.34% | 34 |
|
|
2021
Q2 | $26M | Buy |
389,365
+123,246
| +46% | +$8.04M | 0.37% | 30 |
|
|
2021
Q1 | $16.8M | Buy |
266,119
+6,496
| +3% | +$404K | 0.29% | 47 |
|
|
2020
Q4 | $16.1M | Buy |
259,623
+18,874
| +8% | +$1.16M | 0.3% | 50 |
|
|
2020
Q3 | $14.5M | Buy |
240,749
+42,560
| +21% | +$2.56M | 0.31% | 54 |
|
|
2020
Q2 | $11.7M | Buy |
+198,189
| New | +$11.9M | 0.24% | 75 |
|
|
2020
Q1 | – | Sell |
-271,371
| Closed | -$17.4M | – | 716 |
|
|
2019
Q4 | $17.4M | Sell |
271,371
-7,607
| -3% | -$436K | 0.79% | 17 |
|
|
2019
Q3 | $14.1M | Buy |
278,978
+16,761
| +6% | +$788K | 0.32% | 55 |
|
|
2019
Q2 | $11.9M | Buy |
262,217
+116,476
| +80% | +$5.43M | 0.29% | 62 |
|
|
2019
Q1 | $6.95M | Buy |
+145,741
| New | +$7.26M | 0.19% | 87 |
|
|
2018
Q4 | – | Sell |
-154,387
| Closed | -$9.58M | – | 595 |
|
|
2018
Q3 | $9.58M | Buy |
154,387
+18,099
| +13% | +$1.07M | 0.36% | 45 |
|
|
2018
Q2 | $7.54M | Buy |
136,288
+74,230
| +120% | +$4.01M | 0.34% | 45 |
|
|
2018
Q1 | $3.92M | Buy |
62,058
+6,965
| +13% | +$448K | 0.22% | 72 |
|
|
2017
Q4 | $3.38M | Buy |
55,093
+13,200
| +32% | +$826K | 0.24% | 63 |
|
|
2017
Q3 | $2.67M | Buy |
41,893
+3,946
| +10% | +$230K | 0.24% | 63 |
|
|
2017
Q2 | $2.11M | Buy |
37,947
+2,250
| +6% | +$122K | 0.21% | 64 |
|
|
2017
Q1 | $1.94M | Buy |
35,697
+2,271
| +7% | +$125K | 0.24% | 54 |
|
|
2016
Q4 | $1.95M | Sell |
33,426
-891
| -3% | -$48.7K | 0.28% | 54 |
|
|
2016
Q3 | $1.85M | Sell |
34,317
-198
| -0.6% | -$12.7K | 0.28% | 53 |
|
|
2016
Q2 | $2.54M | Buy |
34,515
+3,220
| +10% | +$228K | 0.4% | 39 |
|
|
2016
Q1 | $2M | Buy |
31,295
+1,821
| +6% | +$115K | 0.45% | 47 |
|
|
2015
Q4 | $2.03M | Buy |
+29,474
| New | +$1.95M | 0.48% | 44 |
|
|
2013
Q4 | $360K | Buy |
+6,106
| New | +$311K | 0.09% | 311 |
|
Other funds holding BMY
Pacer Advisors's BMY Position: Q2 2026 in Review
Pacer Advisors increased its Bristol-Myers Squibb (BMY) stake by 0.85% in Q2 2026, buying an estimated $3.88M and bringing the position to 7,995,711 shares worth $461M. The position accounts for 1.17% of the portfolio, ranked #2.
Pacer Advisors first reported a position in BMY in Q4 2013 and has held it in 42 quarters since. The position peaked at $565M in Q3 2024. 2,516 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Pacer Advisors held 7,995,711 shares of Bristol-Myers Squibb worth $461M as of Q2 2026.
- Pacer Advisors bought 67,613 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.88M.
- Bristol-Myers Squibb made up 1.17% of Pacer Advisors's portfolio in Q2 2026, its #2 holding.
- Pacer Advisors first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 42 quarters since.
- Pacer Advisors's Bristol-Myers Squibb position peaked at $565M in Q3 2024.
- 2,516 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.